SCHEDULE: Morgan Stanley Adjusts Arbutus Biopharma Stake

Morgan Stanley and its subsidiary, Morgan Stanley Investment Management Inc., have updated their Schedule 13G filing regarding their beneficial ownership of Arbutus Biopharma Corp. common shares.

Summary

• Morgan Stanley and its subsidiary, Morgan Stanley Investment Management Inc., have filed an amendment to their Schedule 13G, reporting changes in their beneficial ownership of Arbutus Biopharma Corp. common shares.
• As of September 30, 2026, Morgan Stanley beneficially owns 18,682,708 shares, representing 12.2% of the class.
• Morgan Stanley Investment Management Inc. beneficially owns 17,376,366 shares, representing 11.3% of the class.
• Both entities are registered under Delaware and are classified as investment advisers (IA) and holding companies (HC) respectively, with shared voting and dispositive power over the reported shares.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a neutral filing, primarily reporting changes in beneficial ownership without new strategic or financial performance information.

Positives

• Morgan Stanley Investment Management Inc. is identified as a wholly-owned subsidiary of Morgan Stanley, clarifying the reporting structure.
• The filing confirms that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Negatives

• The filing does not provide any new financial performance data or strategic updates for Arbutus Biopharma Corp.

Risks

• The filing does not explicitly mention any new risks or challenges.

Future Outlook

No forward-looking statements or guidance are provided in this filing, as it pertains to beneficial ownership reporting.

Management Comments

• Morgan Stanley and Morgan Stanley Investment Management Inc. agree that this Schedule 13G is filed on behalf of each of the parties, unless differentiated.
• The securities reported on by Morgan Stanley as a parent holding company are owned, or may be deemed to be beneficially owned, by Morgan Stanley Investment Management Inc., a wholly-owned subsidiary of Morgan Stanley.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are routine disclosures for institutional investors exceeding a certain ownership threshold. This filing indicates ongoing investment activity by Morgan Stanley entities in Arbutus Biopharma Corp., a biotechnology company.

Comparison to Industry Standards

• This filing is a standard Schedule 13G, which is a regulatory requirement for institutional investors holding more than 5% of a company's voting stock. The format and content align with typical filings of this nature.

Stakeholder Impact

• Shareholders: The filing provides transparency regarding significant institutional ownership, which can influence market perception and trading activity.

Next Steps

• Continued monitoring of Arbutus Biopharma Corp. by Morgan Stanley and Morgan Stanley Investment Management Inc. as per their investment strategies.

Key Dates

Keywords

Arbutus Biopharma Corp, Morgan Stanley, Schedule 13G, Beneficial Ownership, Investment Management, Common Shares, Securities Exchange Act